Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04691570 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
A Phase 2 study, sponsored by Annexon.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT04691570 is a Phase 2 study that has completed, run by Annexon. The registered enrollment target is 7 participants.
The verdict
NCT04691570, a Phase 2 study, has completed, sponsored by Annexon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of ANX005 in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).
Interventions
- DRUG ANX005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-11-10 |
| Est. Completion | 2023-01-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04691570
The ClinicalTrials.gov registry entry for NCT04691570 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Annexon, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ANX005 is the first listed.
NCT04691570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04691570 about?
NCT04691570 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)". This study will evaluate the safety and tolerability of ANX005 in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).
What is the current status of trial NCT04691570?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2021-11-10. Estimated completion is 2023-01-17.
What interventions are being tested in trial NCT04691570?
The interventions under investigation include: ANX005 (DRUG).
Who is sponsoring clinical trial NCT04691570?
This trial is sponsored by Annexon, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.